

|                         |  |
|-------------------------|--|
| <b>NCT ID</b>           | NCT05493683  |
| <b>Title</b>            | Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer   |
| <b>Phase</b>            | Phase 2  |
| <b>Date Added</b>       | 2022-08-09   |
| <b>Location</b>         | China,China,China,China,China,China  |
| <b>Prior IO Allowed</b> | Yes  |
| <b>CRC-directed</b>     | Yes  |
| <b>Status</b>           | Recruiting   |
| <b>Drugs</b>            | Disitamab vedotin, Tislelizumab  |
| <b>Tags</b>             | MSI-H/ MMRd, MSS/ MMRp   |
| <b>NCT ID</b>           | NCT05491317  |
| <b>Title</b>            | A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors                                     |
| <b>Phase</b>            | Phase 1, Phase 2   |
| <b>Date Added</b>       | 2022-08-08   |
| <b>Location</b>         | France   |
| <b>Prior IO Allowed</b> | Yes  |
| <b>CRC-directed</b>     | No   |
| <b>Status</b>           | Terminated   |
| <b>Drugs</b>            | Pembrolizumab  |
| <b>Tags</b>             | MSI-H/ MMRd, MSS/ MMRp   |
| <b>NCT ID</b>           | NCT05491083  |
| <b>Title</b>            | Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer   |
| <b>Phase</b>            | Phase 1, Phase 2   |
| <b>Date Added</b>       | 2022-08-08   |
| <b>Location</b>         | Singapore  |
| <b>Prior IO Allowed</b> | No   |
| <b>CRC-directed</b>     | No   |
| <b>Status</b>           | Recruiting   |
| <b>Drugs</b>            | Pembrolizumab & ADG106 (Phase Ib), Pembrolizumab & ADG106 (Phase II)   |
| <b>Tags</b>             | MSI-H/ MMRd, MSS/ MMRp   |
| <b>NCT ID</b>           | NCT05487235  |
| <b>Title</b>            | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors |
| <b>Phase</b>            | Phase 1  |
| <b>Date Added</b>       | 2022-08-04   |
| <b>Location</b>         | Argentina<br>Australia<br>Brazil<br>Canada<br>Korea, Republic of<br>New Zealand  |
| <b>Prior IO Allowed</b> | Yes  |
| <b>CRC-directed</b>     | No   |
| <b>Status</b>           | Completed  |
| <b>Drugs</b>            | Atezolizumab, GDC-1971, Omeprazole   |
| <b>Tags</b>             | MSI-H/ MMRd, MSS/ MMRp   |
| <b>NCT ID</b>           | NCT05482516  |

|                         |   |
|-------------------------|---|
| <b>Title</b>            | Evaluating Novel Therapies in ctDNA Positive GI Cancers   |
| <b>Phase</b>            | Phase 3   |
| <b>Date Added</b>       | 2022-08-01  |
| <b>Location</b>         | District of Columbia, United States<br>New Jersey, United States  |
| <b>Prior IO Allowed</b> | No  |
| <b>CRC-directed</b>     | Yes   |
| <b>Status</b>           | Recruiting  |
| <b>Drugs</b>            | Atezolizumab, Bevacizumab, Avastin, Tecentriq   |
| <b>Tags</b>             | MSI-H/ MMRd, MSS/ MMRp  |
| <hr/>                   |   |
| <b>NCT ID</b>           | NCT05480306   |
| <b>Title</b>            | Phase 2 Study of DKN-01 in Colorectal Cancer  |
| <b>Phase</b>            | Phase 2   |
| <b>Date Added</b>       | 2022-07-29  |
| <b>Location</b>         | Arizona, United States<br>California, United States<br>Florida, United States<br>Louisiana, United States<br>Maryland, United States<br>Missouri, United States<br>New York, United States<br>North Carolina, United States<br>South Carolina, United States<br>South Dakota, United States<br>Tennessee, United States<br>Washington, United States<br>Wisconsin, United States<br>Germany<br>Korea, Republic of |
| <b>Prior IO Allowed</b> | No  |
| <b>CRC-directed</b>     | Yes   |
| <b>Status</b>           | Completed   |
| <b>Drugs</b>            | Bevacizumab, DKN-01, FOLFIRI, FOLFOX  |
| <b>Tags</b>             | MSS/ MMRp   |
| <hr/>                   |   |
| <b>NCT ID</b>           | NCT05479812   |
| <b>Title</b>            | Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors  |
| <b>Phase</b>            | Phase 1   |
| <b>Date Added</b>       | 2022-07-29  |
| <b>Location</b>         | Arizona, United States<br>Florida, United States<br>Georgia, United States<br>Illinois, United States<br>Indiana, United States<br>Minnesota, United States<br>New Jersey, United States<br>New York, United States<br>Oregon, United States<br>Texas, United States  |
| <b>Prior IO Allowed</b> | Yes   |
| <b>CRC-directed</b>     | No  |
| <b>Status</b>           | Recruiting  |
| <b>Drugs</b>            | Pembrolizumab, WTX-124  |
| <b>Tags</b>             | MSI-H/ MMRd   |

|                         |   |
|-------------------------|---|
| <b>NCT ID</b>           | NCT05464030   |
| <b>Title</b>            | Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)   |
| <b>Phase</b>            | Phase 1   |
| <b>Date Added</b>       | 2022-07-19  |
| <b>Location</b>         | California, United States<br>Rhode Island, United States<br>Texas, United States<br>Canada<br>Japan<br>South Korea<br>Spain |
| <b>Prior IO Allowed</b> | Yes   |
| <b>CRC-directed</b>     | Yes   |
| <b>Status</b>           | Recruiting  |
| <b>Drugs</b>            | M9140   |
| <b>Tags</b>             | MSI-H/ MMRd, MSS/ MMRp  |

---

|                         |   |
|-------------------------|---|
| <b>NCT ID</b>           | NCT05438342   |
| <b>Title</b>            | An Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for Recurrence and Metastasis |
| <b>Phase</b>            | Not Applicable  |
| <b>Date Added</b>       | 2022-06-29  |
| <b>Location</b>         | China   |
| <b>Prior IO Allowed</b> | Yes   |
| <b>CRC-directed</b>     | No  |
| <b>Status</b>           | Recruiting  |
| <b>Drugs</b>            | Chemotherapy?checkpoint immunotherapy, targeted therapy   |
| <b>Tags</b>             | MSI-H/ MMRd, MSS/ MMRp  |

---

|                         |  |
|-------------------------|--|
| <b>NCT ID</b>           | NCT05426005  |
| <b>Title</b>            | Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer |
| <b>Phase</b>            | Phase 1, Phase 2   |
| <b>Date Added</b>       | 2022-06-21   |
| <b>Location</b>         | China  |
| <b>Prior IO Allowed</b> | Yes  |
| <b>CRC-directed</b>     | Yes  |
| <b>Status</b>           | Recruiting   |
| <b>Drugs</b>            | Cadonilimab  |
| <b>Tags</b>             | MSI-H/ MMRd  |